About
Mediphage Bioceuticals represents a highly motivated team of multidisciplinary professionals that focuses on state-of-the art research, education and technology transfer. We manipulate naturally occurring phage entities in order to develop new therapeutics, vaccines, antivirals, cosmeceuticals, as well as industrial applications. Our goal is to engineer and technologically transfer novel therapeutics that meet the global need for treatment in a multitude of areas including: a universal influenza vaccine; a universal gram positive therapeutic, a universal gram-negative therapeutic, a universal mycobacterial therapeutic/vaccine. Phages represent a simplistic solution to a complex problem. Although different phages vary with respect to thermostability, they can be freeze-dried rendering them temperature-resistant and thus are capable of packaging and shipping to warmer climates within a reasonable time period. These attributes contribute to the value of these nomadic genetic entities in addition to the endless and priceless reservoir of genetic information they carry to combat human disease on a global scale.
We aim to manipulate phages and their encoded systems to create “smart” biologics that purvey superior therapeutic value and global accessibility, particularly with respect to the treatment of M. tuberculosis, clinically relevant Gram-positive infections, the flu, HIV and ovarian cancer.